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Background and objectives: Mechanical ventilation is the recommended treatment in 
unconscious patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) 
and hypercapenic respiratory failure. But, in resource-poor countries, many of these patients 
are not able to afford this treatment due to financial constraints. The main aim of this study 
was to evaluate the usefulness, safety and cost-effectiveness of bilevel positive airway pressure 
(BiPAP) applied via endotracheal tube in such patients.
Methods: Twenty patients with acute exacerbation of COPD and altered sensorium, who were 
unable to afford ventilatory support, were intubated and BiPAP therapy was provided to these 
patients through the endotracheal tube. The outcome of these patients was studied.
Results: The BiPAP success rate and hospital mortality were 85% (17/20) and 15% (3/20) 
respectively. BiPAP failure was associated with high sequential organ failure assessment 
(SOFA) score at the time of admission (P = 0.002). Improvement in Glasgow coma scale (GCS) 
score (P , 0.001), pH (P = 0.001), PaCO2 (partial pressure of carbon dioxide) (P , 0.001), 
respiratory rate (P , 0.001), and SOFA score (P = 0.001) was observed among the responders 
following 2 hours of therapy. Only one of the responders developed aspiration pneumonitis, as 
a complication. The daily cost of BiPAP therapy was 8.75 times lower than the average cost 
of mechanical ventilation.
Conclusion: This pilot study reveals that this treatment modality could be a safe, cost-
effective and efficacious method of treatment in unconscious patients with acute exacerbation 
of COPD.
Keywords: bilevel positive air way pressure, chronic obstructive pulmonary disease, 
hypercapenic respiratory failure
Introduction
Noninvasive positive pressure ventilation (NIPPV) is a safe and effective means of 
improving gas exchange in acute respiratory failure (ARF).1 There is level I evidence 
to suggest that in patients with acute exacerbation of chronic obstructive pulmonary 
disease (COPD) and hypercapnic respiratory failure, adding noninvasive ventila-
tion to standard therapy decreases the need for endotracheal intubation and reduces 
mortality.2–12
The use of NIPPV to treat ARF is a treatment that is contraindicated in comatose 
patients because of the risk of aspiration. As a result, intubation and mechanical 
ventilation in the intensive care unit remain the only option for such a group of 
patients. In developing countries like India, health care costs of intensive care unit 
(ICU) stay and ventilator support is unaffordable for a large proportion of patients. 
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Moreover, in vast stretches of the country such facilities are 
unavailable. This leaves the treating physician with limited 
therapeutic alternatives.
This work was undertaken to evaluate the effectiveness of 
treating such comatose patients suffering from acute exacer-
bation of COPD, who could not afford the cost of mechanical 
ventilation in an ICU, with bilevel positive airway pressure 
(BiPAP), connected to an endotracheal tube. This approach 
was prompted by a few previous studies demonstrating 
clinical improvement in patients with hypercapnic coma 
following treatment with NIPPV .13–15 In contrast to those 
studies, instead of a face mask, in this study BiPAP was 
applied through an endotracheal tube to enable the periodic 
suctioning of airway secretions to minimize the chances of 
pulmonary aspiration and subsequent pneumonia.
Materials and methods
This prospective observational study was carried out from 
January 2008 to December 2008 in the respiratory interme-
diate care unit of Himalayan Institute Hospital, Deheradun, 
India. This four-bedded unit functions under the direct super-
vision of qualified pulmonologists and is attended round the 
clock by a trained nurse and a dedicated chest therapist with 
training in BiPAP administration. The study was approved 
by the institutional ethics committee, and written informed 
consent was obtained from the nearest accompanying family 
member of each patient.
Consecutive COPD patients with hypercapnic acute 
respiratory failure (partial pressure of carbon dioxide 
[PaCO2] .45 mmHg and pH , 7.25), reduced level of 
consciousness (Glasgow coma scale [GCS] score , 8), who 
were ineligible for NIPPV via facemask and were unable to 
afford the cost of ventilatory support in ICU, were recruited 
in the study. The following exclusion criteria were adopted 
for the study: (1) refusal of the patient’s attendant to per-
form endotracheal intubation, (2) hypoglycemic patients, 
(3) patients with impaired consciousness due to accompany-
ing comorbidities like neurogenic coma, drug-induced altered 
sensorium, (4) patients whose hypoxia could not be corrected 
within 30 minutes of administration of BiPAP.
These patients were intubated tracheally and connected 
with NIPPV (BiPAP ST, Respironics, Inc, Murrysville, PA) 
via T-tube. This connector tube had two ends, one for the 
endotracheal tube and the other for BiPAP, and two ports, one 
for expiration and the other for oxygen. To minimize the risk 
of pulmonary aspiration, patients were kept in a recumbent 
position with the head raised at 45°. A nasogastric tube was 
inserted in all patients. Electrocardiogram (ECG), blood 
oxygen saturation (SpO2), and noninvasive blood pressure 
were monitored continuously. A chest therapist was advised 
to carry out chest and limb physiotherapy and continuous 
watch on vital parameters. The device used in this study 
had the following features: (1) inspiratory positive airway 
pressure (IPAP), 4–30 cm H2O ± 2.5 cm H2O; (2) expiratory 
positive air way pressure (EPAP), 4–25 cm H2O ± 2.5 cm 
H2O; (3) breath rate, 0–30 breaths per minute; (4) timed inspi-
ration, 0.5–3.0 seconds ±10% of the setting; (5) rise time, 
1%–6% ± 25%; (6) ramp duration, 0–45 minutes ±10% of the 
setting. The device also had three alarm levels (high, medium, 
and low) depending on the extent of breathing circuit leakage 
and resulting apnea. The BiPAP was set in the spontaneous/
timed mode, with a backup respiratory rate of 15 breaths per 
minute. The initial IPAP was set at 14 cm H2O. IPAP was 
increased by 2–3 cm H2O over 4 hours as tolerated but did not 
exceed 25 cm H2O. EPAP was begun at 4 cm H2O and was 
increased up to 8 cm H2O, depending on the requirement of 
the patient. Oxygen inhalation was adjusted to maintain SpO2 
between 89% and 92%. Arterial blood gas (ABG) samples 
were obtained from each patient before and after 2 hours of 
initiation of BiPAP. Subsequently, samples were obtained 
every 24 hours or as clinically indicated.
The clinical course of the patient during the BiPAP 
therapy was monitored using GCS score, blood pressure, 
heart rate, respiratory rate, ABG levels, and sequential organ 
failure assessment (SOFA) score. Therapy was considered 
to have failed if at least one of the following occurred: 
(1) worsening of consciousness within 2 hours of initiating 
BiPAP; (2) deterioration of ABG, defined as no improve-
ment or deterioration in pH, PaCO2, and partial pressure 
arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) 
ratio from baseline measurement after 2 and 24 hours of 
BiPAP administration; (3) respiratory or cardiac arrest; and 
(4) development of hemodynamic instability. Treatment was 
considered successful when the patient gained full conscious-
ness and was discharged alive from the hospital.
Short-acting benzodiazepines (midazolam) were advised 
as and when required in some patients who were restless 
and agitated. Patients were extubated once their conscious-
ness increased enough to follow complex verbal command 
irrespective of PaCo2, and were thereafter applied with 
BiPAP via facemask.
Statistical analysis
Comparison of the monitored parameters between patients 
who improved and those who failed in the BiPAP therapy was 
done using Mann–Whitney U test for quantitative variables and 
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Fisher’s exact test for qualitative variables. Progressive change 
with time in both the categories of patients was analyzed using 
the Wilcoxon signed rank test. Kaplan–Meier survival analysis 
was done using log-rank (Mantel–Cox) test. All analyses 
were two-tailed, and P , 0.05 was considered significant. 
Statistical analysis was performed using SPSS Statistics (IBM 
Corporation, Somers, NY) software, version 16.0.
Results
During the study period, a total of 22 patients fulfilled the 
inclusion criteria for the study, attendants of four patients 
declined endotracheal intubation and left the hospital against 
medical advice. One patient’s hypoxic status could not be 
corrected within 30 minutes with BiPAP administration and 
had to be shifted to bag valve mask (Ambu bag) resuscitation. 
Of the 22 patients recruited in the study, two patients were 
shifted to ICU during the course of BiPAP therapy owing 
to the subsequent availability of funds, and hence they 
were excluded from the final analysis. Out of the remaining 
20 patients, 17 responded successfully to the treatment and 
three failed to respond and died.
The baseline characteristics and physiological variables 
of these patients were comparable in almost all respects, 
as shown in Table 1. However, the SOFA score of the suc-
cessfully treated patients was significantly better than in the 
nonresponders (P = 0.004).
Analyzing the progressive course of the treated patients, a 
significant improvement in all the monitored parameters was 
observed among the favorable responders by the end of the 
second hour of treatment. However, the systolic blood pres-
sure remained unchanged at the end of 2 hours. Among the 
nonresponders, no change was observed in any of the moni-
tored parameters at the end of 2 hours. The positive change 
in all the parameters observed among the responders at the 
end of 2 hours was maintained throughout the duration of 
treatment (Table 2).
Among the patients who responded to the treatment, only 
one patient developed lobar pneumonia of the right lower 
lobe, which could be attributed to aspiration pneumonia. It 
resolved on administration of piperacillin-tazobactam for 
8 days. No other complication associated with BiPAP therapy 
was observed in any other patient.
Maximum inspiratory pressure applied during BiPAP 
therapy was similar between the responders and nonre-
sponders [median (range) for responders and nonresponders 
being 17.5 (16.7–19.6) and 18.2 (17.9–19.5) respectively; 
P = 0.379]. The time of administering BiPAP therapy was 
also comparable between the two groups [median (range) 
for responders and nonresponders being 3.8 (2.7–5.0) and 
3.0 (2.0–4.0) respectively; P = 0.469]. The three patients 
who failed on this treatment died on the second, third, and 
fourth days of hospitalization, while the median (range) time 
of hospitalization among the responders was 8 (5–15) days. 
Follow-up until the 14th day showed a significant differ-
ence in survival between the responders and nonresponders 
(P # 0.001; log-rank [Mantel–Cox] test).
Comparing the financial implications of BiPAP therapy 
and mechanical ventilation, the average charges for the former 
was calculated to be INR 2800 (US$62.10) per patient. This 
was based on a daily charge of INR 800 (US$17.74) levied 
by the hospital for administering BiPAP therapy. The cor-
responding daily cost for mechanical ventilation, apart from 
ICU charges, is INR 7000 (US$155.24), and hence, a similar 
duration of mechanical ventilation would have resulted in an 
average cost of INR 24,500 (US$543.34), which is 8.75 times 
higher than the average cost of BiPAP therapy.
Table 1 Patient characteristics of two group and baseline physiological variables in COPD patients with coma
Variable Median (range) P-value
Responders (n = 17)  Nonresponders (n = 3)
Age (years) 60 (38–72) 60 (55–65) 0.957
Gender distribution (M/F) 15/2 2/1 0.404
COPD duration (years) 10 (2–14) 12 (10–20) 0.199
Smoking (pack years) 10 (2–14) 18 (0–20) 0.264
GCS 6 (3–7) 7 (4–7) 0.438
Systolic blood pressure 122 (90–150) 102 (102–122) 0.111
Heart rate (beats/min) 116 (90–136) 132 (124–140) 0.022
Respiratory rate (breaths/min) 28 (22–36) 32 (28–34) 0.145
pH 7.1 (6.9–7.2) 7.1 0.872
PaCO2 28 (22–36) 32 (28–34) 0.559
SOFA score 3 (2–5) 7 (7–8) 0.004
Abbreviations: COPD, chronic obstructive pulmonary disease; F, female; GCS, Glasgow coma scale; M, male; PaCO2, partial pressure of carbon dioxide; SOFA, sequential 
organ failure assessment.
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Discussion
Reported in this study, is the favorable outcome and 
cost-effectiveness of BiPAP therapy, administered through an 
endotracheal tube, in COPD patients with acute type II respira-
tory failure and reduced level of consciousness. Also demon-
strated is that reduced SOFA scores at initiation of treatment 
carries a better prognosis for this modality of treatment. To the 
best of the authors’ knowledge, this is the first study showing 
the potential utility of this therapy in these situations.
Owing to the risk of aspiration, NIPPV is hardly considered 
as a therapeutic option in patients of acute respiratory failure 
with impaired consciousness, and this probably explains the 
paucity of literature on the subject.13–18 Among the limited 
number of studies in this area, the one reported by Scala 
et al13 demonstrated better outcome of NIPPV in patients with 
improved level of consciousness. In their study, success rates 
of 85%, 75%, and 55% was observed in patients with Kelly 
scores of 1, 2, and 3 respectively.10 However, comparing the 
response to NIPPV between COPD patients with a GCS score 
of $8 and those with a score below 8, Diaz and coworkers 
have recently reported similar success rates (defined as avoid-
ance of endotracheal intubation and survival for 24 hours after 
discharge from ICU) and hospital mortality rates in the two 
groups.14 Zhu et al15 have also reported successful treatment 
with NIPPV in 11 of 13 comatose patients. In another study 
conducted on 30 patients, three patients were comatose, of 
which two were successfully treated with NIPPV .16 In compari-
son with these studies, a different methodology was adopted 
for administering BiPAP therapy in this study. Instead of 
BiPAP being applied via face mask, an endotracheal tube was 
used for administration, and a better success rate and lower 
mortality was observed compared with the previous studies. 
The better outcome could be due to reduction of the chances 
of aspiration and subsequent pneumonia or sepsis following 
the application of an endotracheal tube. Moreover, administra-
tion of this therapy through endotracheal tube allows for more 
effective delivery of inspiratory pressure to the airways and 
minimizes the chances of leakage of the same through potential 
air spaces underneath an ill-fitting face mask. Isolated case 
reports have also described successful application of NIPPV 
in selected patients with hypercapnic coma.17,18
Certain precautions were taken before using the BiPAP 
ST device for an off-label application. Firstly, to avoid power 
failures, the device was used only under the back-up of uninter-
rupted power supply (UPS). Secondly, the on-site availability 
of a trained respiratory therapist was ensured around the clock 
in order to recognize and respond to any untoward complica-
tion arising during the course of the therapy. A maximum FiO2 
of 45%–50% can be delivered with this device, which can 
impair its utility in certain cases, and accordingly the decision 
Table 2 Comparison of vital signs and ABG variables with length of BiPAP administration between two groups
Variable Baseline At 2 hours P-value  
(within the group)
At enda P-value  
(within the group)
Systolic BP 
Responder (n = 17) 
Nonresponder (n = 3)
122 ± 15.9
104 ± 16.0
117 ± 9.1
102 ± 7.2
 
0.177 
0.102
114 ± 11.2
104 ± 14.4
 
0.039 
1.000
Heart rate 
Responder (n = 17)  
Nonresponder (n = 3)
113 ± 16.0
120 ± 22.2
101 ± 11.4
119 ± 20.4
 
0.001 
0.593
86.7 ± 4.5
123 ± 23.3
 
0.003 
0.109
Respiratory rate 
Responder (n = 17) 
Nonresponder (n = 3)
28.3 ± 3.8
29.3 ± 2.3
23.3 ± 3.5
30 ± 3.4
 
,0.001 
0.902
18.3 ± 2.6
30.6 ± 5.7
 
,0.001 
0.593
pH 
Responder (n = 17) 
Nonresponder (n = 3)
7.01 ± 0.09
7.1 ± 1.09
7.12 ± 0.07
7.11 ± 1.0
 
0.001 
1.000
7.31 ± 0.04
7.08 ± 0.15
 
,0.001 
0.420
PaCO2 
Responder (n = 17) 
Nonresponder (n = 3)
97.1 ± 14.3
93.6 ± 4.0
78 ± 12.3
95.3 ± 10.5
 
,0.001 
1.000
55.5 ± 5.9
106 ± 7.2
 
,0.001 
0.109
SOFA score 
Responder (n = 17) 
Nonresponder (n = 3)
5.2 ± 0.7
7.3 ± 0.5
3.2 ± 0.3
6.6 ± 0.2
 
0.001 
0.626
0.35 ± 0.6
6.0 ± 1.0
 
,0.001 
0.105
GCS 
Responder (n = 17) 
Non-responder (n = 3)
5.8 ± 1.0
6.3 ± 1.1
10.5 ± 1.7
7.0 ± 1.7
 
,0.001 
0.157
14.6 ± 2.6
4.3 ± 0.5
 
,0.001 
0.109
Note: a“At end” signifies the termination of BiPAP therapy.
Abbreviations: ABG, arterial blood gas; BiPAP, bilevel positive airway pressure; BP, blood pressure; GCS, Glasgow coma scale; PaCO2, partial pressure of carbon dioxide; 
SOFA, sequential organ failure assessment.
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was made to give a trial of 30 minutes with this device and then 
to shift the patient to bag valve mask (Ambu bag) resuscitation 
if the hypoxic state did not get corrected.
Apart from the modification in the method of admin-
istering BiPAP, several important revelations emerged 
from this pilot study. Firstly, SOFA score was found to 
be significantly different between the responders and the 
nonresponders, which probably implies poor prognosis of 
this treatment modality in COPD patients with multisystem 
involvement. Secondly, in all responders, positive response 
was observed quite early in the treatment, ie, by 2 hours 
of initiating BiPAP therapy, while non responders showed 
progressive deterioration in all the parameters monitored at 
this time-point. This suggests that potential responders can 
be identified relatively early in course of treatment and the 
nonresponders can be considered for ventilator therapy at the 
end of 2 hours. Thirdly, the mean duration of BiPAP therapy 
was 3.6 days among the responders, while the mean dura-
tion of hospitalization was 8.4 days. This suggests that these 
patients could be successfully weaned from NIPPV therapy 
and did not require any respiratory support over a significant 
duration of hospital stay subsequent to this therapy.
Although this study was conducted on a small sample 
size, which included only three nonresponders, the promis-
ing results obtained by us merit further validation in a more 
elaborate randomized trial, and the results of BiPAP therapy 
need to be compared with the outcome of ventilator therapy. 
In the event of these initial findings being authenticated, this 
treatment modality can offer a valuable alternative to the more 
expensive and technically demanding ventilator therapy, par-
ticularly in resource-constrained situations. However, it would 
be apt to use a suitable and safe device for this purpose that can 
deliver adequate inspiratory and expiratory pressure through 
an endotracheal tube, possess satisfactory power back-up, 
and provide alarm signals in case of emergency. Hybrid 
ventilators, which perform both pressure and volume preset 
ventilation and are substantially cheaper than an ICU ventila-
tor, could be an appropriate alternative in this regard.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Ram FS, Picot J, Lightowler J, et al. Noninvasive positive pressure 
ventilation for treatment of respiratory failure due to exacerbations of 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 
2004;3:CD004104.
  2.  Meduri GU. Noninvasive positive-pressure ventilation in patients with 
acute respiratory failure. Clin Chest Med. 1996;17:513–553.
  3.  Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic 
pulmonary edema with continuous positive airway pressure delivered 
by face mask. N Engl J Med. 1991;325:1825–1830.
  4.  Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of 
nasal ventilation in acute ventilatory failure due to chronic obstructive 
airways disease. Lancet. 1993;341:1555–1557.
  5.  Rasanen J, Heikkila J, Downs J, et al. Continuous positive airway 
pressure by face mask in acute cardiogenic pulmonary edema. Am J 
Cardiol. 1985;55:296–300.
  6.  Ahmed AH, Fenwick L, Angus RM, et al. Doxapram in the treatment 
of type II respiratory failure complicating chronic airflow obstruction. 
Thorax. 1992;1:858.
  7.  Meduri GU, Turner RE, Abou-Shala N, et al. Noninvasive positive 
pressure ventilation via face mask: first-line intervention in patients 
with acute hypercapnic and hypoxemic respiratory failure. Chest. 
1996;109:179–193.
  8.  Daskalopoulou E, Tsara V , Fekete K, et al. Treatment of acute respira-
tory failure in COPD patients with positive airway pressure via nasal 
mask (NPPV). Chest. 1993;103 Suppl:271S.
  9.  Keenan SP, Kernerman PD, Cook DJ, et al. The effect of noninva-
sive positive pressure ventilation on mortality in patients admitted 
with acute respiratory failure: a meta-analysis. Crit Care Med. 
1997;25:1685–1692.
  10.  Tamanna S, Ullah MI. Use of noninvasive ventilation in general 
ward for the treatment of respiratory failure. J Miss State Med Assoc. 
2011;52:278–281.
  11.  Cabrini L, Antonelli M, Savoia G, et al. Non-invasive ventilation out-
side of the intensive care unit: an Italian survey. Minerva Anestesiol. 
2011;77:313–322.
  12.  Cabrini L, Monti G, Pischedda A, et al. Non-invasive ventilation outside 
intensive care unit for acute respiratory failure: the perspective of a 
general ward nurse. Minerva Anestesiol. 2009;75:427–433.
  13.  Scala R, Naldi M, Archinucci I, et al. Noninvasive positive pressure 
ventilation in patients with acute exacerbations of COPD and varying 
levels of consciousness. Chest. 2005;128:1657–1666.
  14.  Diaz GG, Alcaraz AC, Talavera JC, et al. Noninvasive positive-pressure 
ventilation to treat hypercapnic coma secondary to respiratory failure. 
Chest. 2005;127:952–960.
  15.  Zhu L, Niu SF, Li YQ, et al. Effectiveness of mechanical ventila-
tion via face mask on comatose patients with chronic obstructive 
pulmonary   disease induced respiratory failure. Chin Crit Care Med. 
1997;9:28–30.
  16.  Benhamou D, Girault C, Faure C, et al. Nasal mask ventilation in acute 
respiratory failure: experience in elderly patients. Chest. 1992;102: 
912–917.
  17.  Scala R, Archinucci I, Naldi, et al. Noninvasive nasal ventilation in a 
case of hypercapnic coma. Minerva Anestesiol. 1997;63:245–248.
  18.  Adnet F, Racine SX, Lapostolle F, et al. Full reversal of hypercapnic 
coma by noninvasive positive pressure ventilation. Am J Emerg Med. 
2001;19:244–246.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
325
Role of BiPAP among comatose patients of COPD